期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 51, 期 18, 页码 5663-5679出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm8004527
关键词
-
Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies cultriinating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3 beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3 beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据